Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 3,497 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Completed Phase 3 Interventional Results available

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

NCT03523585
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan, Capecitabine, Lapatinib, Trastuzumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
41
States / cities
Chandler, Arizona • Los Angeles, California • Monterey, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults

NCT01540474
View directory record Official record
Conditions
Malaria
Interventions
Group 1: 10 ug FMP012 with 2 ug GLA-SE, Group 2: 10 ug FMP012 with 5 ug GLA-SE, 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE, Controlled group-Challenged Only: no vaccination
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Early Levothyroxine Post Radioactive Iodine

NCT01950260
View directory record Official record
Conditions
Graves' Disease
Interventions
Levothyroxine, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome

NCT00362440
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
Leptin, Pioglitazone or metformin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Topical Vancomycin for Neurosurgery Wound Prophylaxis

NCT02284126
View directory record Official record
Conditions
Infection, Surgery, Nervous System Diseases
Interventions
Vancomycin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

NCT00943826
View directory record Official record
Conditions
Glioblastoma
Interventions
Bevacizumab, Temozolomide, Radiation therapy, Placebo
Drug · Radiation
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 24, 2026, 1:15 AM EDT
Not listed Phase 4 Interventional

Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use

NCT03364218
View directory record Official record
Conditions
Bronchiolitis Acute
Interventions
N-Acetyl Cysteine
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
1 Week to 2 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 2 Interventional

Effectiveness of Adding Morphine to Intraosseous Vancomycin for Pain Control in Total Knee Arthroplasty

NCT06716749
View directory record Official record
Conditions
Primary Total Knee Arthroplasty, Intraosseous Morphine Injection, Knee Osteoarthritis
Interventions
Morphine, Vancomycin
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 24, 2026, 1:15 AM EDT
Terminated Phase 1 Interventional

BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES

NCT03658135
View directory record Official record
Conditions
Primary Tauopathies, Corticobasal Degeneration Syndrome, Frontotemporal Lobar Degeneration With Tau Inclusions, MAPT Mutation Carriers, Symptomatic, Traumatic Encephalopathy Syndrome, Nonfluent Aphasia, Progressive
Interventions
BIIB092, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

NCT02699450
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Faricimab, Ranibizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
60
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy

NCT00195013
View directory record Official record
Conditions
Peripheral Neuropathy, Breast Cancer
Interventions
glutamine, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 24, 2026, 1:15 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

NCT06515418
View directory record Official record
Conditions
Obesity
Interventions
Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo
Drug
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
55 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
Mesa, Arizona • Los Angeles, California • Montclair, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Of An Advanced Care Decision Aid Among Patients And Physicians_Matlock

NCT01190488
View directory record Official record
Conditions
Palliative Care, Decision Making, Decision Support Techniques, Decision Support Systems, Clinical, Hospices
Interventions
End-of-Life / Advanced Care Decision Aid, Active Comparator
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Not applicable Interventional

Balanced (Egg) Protein During Obesity Reduction: Differential Responses of Insulin Resistance by Race

NCT03771261
View directory record Official record
Conditions
Pre Diabetes, Obesity
Interventions
Weight Loss, Egg Protein
Behavioral · Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 24, 2026, 1:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

NCT05216510
View directory record Official record
Conditions
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Interventions
TNX-2110, TNX-2120, TNX-2130, CANDIN, Diluent
Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 24, 2026, 1:15 AM EDT
Terminated Phase 2 Interventional

Serum-derived Bovine Immunoglobulin Effect on Mucositis

NCT04239261
View directory record Official record
Conditions
Mucositis
Interventions
SBI, Placebo
Dietary Supplement
Lead sponsor
MercyOne Des Moines Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 24, 2026, 1:15 AM EDT
Recruiting Phase 4 Interventional

Postpartum Evaluation of Nifedipine and Enalapril for Hypertension

NCT07023003
View directory record Official record
Conditions
Hypertension in Pregnancy
Interventions
Enalapril 10mg QD, Nifedipine 30mg XL BID
Drug
Lead sponsor
Nebraska Methodist Health System
Other
Eligibility
19 Years and older · Female only
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 24, 2026, 1:15 AM EDT
Recruiting Not applicable Interventional

GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health)

NCT06356220
View directory record Official record
Conditions
Celiac Disease in Children, Nutrition Disorder, Child
Interventions
Gluten-Free Diet Education
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 1 Interventional

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

NCT02506023
View directory record Official record
Conditions
Hemophilia A
Interventions
Desmopressin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 24, 2026, 1:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

NCT03737643
View directory record Official record
Conditions
Advanced Ovarian Cancer
Interventions
Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
1,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
26
States / cities
Foothill Ranch, California • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

NCT02954601
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ORMD-0801 (qd), ORMD-0801 (bid), ORMD-0801 (tid), Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 24, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

NCT01064401
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a, Daclizumab High Yield Process Placebo
Biological · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
46
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 24, 2026, 1:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03937219
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Cabozantinib, Nivolumab, Ipilimumab, Cabozantinib-matched placebo
Drug · Biological
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
30
States / cities
La Jolla, California • Orange, California • Boca Raton, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 1:15 AM EDT